Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
NCT06914661 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-07-08
Summary
This study analyzes the use of DS8201 in the treatment of metastatic breast cancer in the real world by analysis, exploring whether there are differences in effectiveness and safety between real-world conditions and clinical trials.
Conditions
- Breast Cancer Metastatic
- Efficacy and Safety
Sponsors & Collaborators
-
The First Hospital of Jilin University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-25
- Primary Completion
- 2025-08-30
- Completion
- 2025-10-30
Countries
- China
Study Locations
More Related Trials
-
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
NCT05367739 ·Status: COMPLETED
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
NCT06784921 ·Status: RECRUITING
-
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06445400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06316531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
NCT03366428 ·Status: COMPLETED ·Phase: PHASE1
-
B002 in Patients With HER2-positive Breast Cancer
NCT04382352 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
NCT06641544 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776 ·Status: RECRUITING
-
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
NCT02947061 ·Status: UNKNOWN ·Phase: PHASE2
-
Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study
NCT05231863 ·Status: UNKNOWN
-
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
NCT05838066 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT06375707 ·Status: RECRUITING ·Phase: PHASE2
-
The Rechallenge of ADCs in MBC Patients
NCT05571618 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
NCT04385563 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
NCT05979220 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
NCT04927481 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961 ·Status: RECRUITING ·Phase: PHASE3
-
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT07018427 ·Status: ACTIVE_NOT_RECRUITING
-
SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases
NCT06210438 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Real World Study of Sacituzumab Govitecan
NCT06966141 ·Status: RECRUITING